CGRP: A new migraine target, a new era in migraine therapy

Loading Map....

Date/Time
Date(s) - 27/10/2017
8:00 am - 9:00 am

Location
Baycrest - Classroom ABC

Categories


City-Wide Neurology Grand Rounds

“CGRP: A new migraine target, a new era in migraine therapy”

DR. DAVID DODICK

Professor of Neurology, Mayo Clinic, Phoenix, Arizona

Learning Objectives:

• To describe the rationale for targeting calcitonin gene-related peptide and its receptor for the acute and preventive treatment of migraine

• To discuss the safety and efficacy evidence to support the use of CGRP receptor antagonists and CGRP monoclonal antibodies for the treatment of migraine and other headache disorders

• To identify other promising peptide targets for the treatment of migraine and other headache disorders

Date: Friday, October 27, 2017

Time: 8:00 – 9:00 am

Location*: West Wing 2-401 (Main Auditorium), Toronto Western Hospital

*This event will be available via both videoconference and webcast:

  • Baycrest – Classrooms ABC, 2nd floor
  • St. Michael’s Hospital – 3-054 Shuter
  • Sunnybrook HSC – Room A450
  • WEBCAST – visit website http://webcast.otn.ca/, under Live Events, search for TSM #76029408

**For registration, please contact your Telehealth Coordinator (TSM #76029408)**

The Special Academic Events in Neurology is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada iversity Rounds

Supported through formal Partnership with the Division of Neurology by:

Allergan Inc., Biogen Idec Canada Inc., EMD Serono Canada Inc., Grifols Canada Ltd., Novartis Pharmaceuticals Canada Inc., Sanofi Genzyme Canada, UCB Canada Inc.